Moderna (MRNA) ended the recent trading session at $31.25, demonstrating a -2.95% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.01%. Elsewhere, the Dow ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

International Business Machines said Thursday that it had joined forces with Moderna for a case study that evidenced quantum ...

The healthcare leader posted adjusted earnings per share of $1.26 for the quarter, slightly above the consensus estimate of ...

J.P. Morgan’s U.S. equity research analysts compiled their list of “most compelling structural and tactical short ideas” for ...